Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 586.00 | |
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM). |
Targets&IC50 | PPARγ (human):15 μM, GR:32.5 μM, ERβ:15.2 μM, PPARδ (human):6 μM, PPARα (human):77 nM |
In vitro | NXT629 is a potent and selective antagonist of PPAR-α(human PPARα,IC50 of 77 nM), shows high selectivity over other nuclear hormone receptor, [2]. |
In vivo | NXT629 has poor oral bioavailability in mice and rats.?NXT629 (30 mg/kg, i.p., daily for 6 weeks) delays growth of subcutaneous SKOV-3 tumors in nude mice, inhibits growth of subcutaneous B16F10 tumors in C57Bl/6 mice.?NXT629 (30 mg/kg, i.p.) is weakly anti-angiogenic against FGF-induced angiogenesis.?NXT629 (3, 30 mg/kg, i.p.) inhibits experimental metastasis of B16F10 melanoma cells to the mouse lung[2]. |
Molecular Weight | 609.78 |
Formula | C35H39N5O3S |
CAS No. | 1454925-59-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (204.99 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NXT629 1454925-59-7 Endocrinology/Hormones Estrogen/progestogen Receptor NXT 629 NXT-629 inhibitor inhibit